Synthetic Biology Market to Show Favorable Growth Globally by 2024 | Hexa ResearchMedgadget (blog)The global Synthetic Biology Market is fueled by extensive research in DNA sequencing and rising governmental support. The growing importance of synthetic… Continue reading
KETV OmahaFDA panel endorses cancer therapy performed in clinical trials at Nebraska MedicineKETV OmahaA Food and Drug Administration panel this week endorsed what could be a groundbreaking cancer treatment. The panel of 10 voted unanimously to recomme… Continue reading
KETV OmahaFDA panel endorses cancer therapy performed in clinical trials at Nebraska MedicineKETV OmahaA Food and Drug Administration panel this week endorsed what could be a groundbreaking cancer treatment. The panel of 10 voted unanimously to recomme… Continue reading
Nasdaq |
A New Cancer Treatment Is on the Way — and Cancer Better Be Scared
Nasdaq Chimeric antigen receptor T–cell therapy, or CAR-T, is a new approach involving the re-engineering of a patient’s T–cells so that they can better find and destroy cancer cells. T–cells are collected from a patient, sent off to a facility where they are … |
Quartz |
Marc Andreessen says he’s reading these eight provocative books to better understand our world
Quartz … “what do nerds do on nights and weekend,” what he called the single most reliable source of new ideas adopted by the broader culture and economy (if interested, check out cryptocurrency, biohacking, quantified self, synthetic biology, virtual … |
|
Stand Up To Cancer, St. Baldrick’s Foundation hail green light for CAR T cell therapy
EurekAlert (press release) “SU2C and the St. Baldrick’s Foundation have committed millions of dollars to the development of the chimeric antigen receptor (CAR) T cell therapy,” said Sung Poblete, PhD, RN, president and CEO of SU2C. “The Dream Team has especially investigated … |
|
Stand Up To Cancer, St. Baldrick’s Foundation hail green light for CAR T cell therapy
EurekAlert (press release) “SU2C and the St. Baldrick’s Foundation have committed millions of dollars to the development of the chimeric antigen receptor (CAR) T cell therapy,” said Sung Poblete, PhD, RN, president and CEO of SU2C. “The Dream Team has especially investigated … |